MTFB - Motif Bio plc

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
8.50
0.00 (0.00%)
At close: 11:37AM EDT
Stock chart is not supported by your current browser
Previous Close8.50
Open8.70
Bid8.00 x 100
Ask9.00 x 500
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume2,661
Market Cap126.766M
Beta0.56
PE Ratio (TTM)N/A
EPS (TTM)-3.88
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.75
Trade prices are not sourced from all markets
  • GlobeNewswire19 days ago

    Motif Bio Announces Resignation of Robert Bertoldi from Board of Directors

    NEW YORK, July 03, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Robert Bertoldi has informed the Company of his decision ...

  • GlobeNewswirelast month

    Result of Annual General Meeting

    NEW YORK, June 19, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual General Meeting held earlier today, all resolutions ...

  • Zacks Small Cap Researchlast month

    MTFB: Completes Submission of NDA for Iclaprim

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. In addition, the U.S. Food and Drug Administration (FDA) has granted iclaprim orphan drug designation (ODD) for the treatment of bacterial infections in patients with cystic fibrosis caused by Staphylococcus aureus.

  • GlobeNewswirelast month

    Motif Bio Submits NDA for Iclaprim

    NEW YORK, June 14, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the completion of its rolling submission of a New Drug ...

  • GlobeNewswirelast month

    Motif Bio Announces New Iclaprim Data Presented at ASM Microbe 2018

    Pooled efficacy and safety data from REVIVE Phase 3 trials presented Data also published in peer-reviewed journal, International Journal of Antimicrobial Agents NEW YORK, June 11, 2018-- Motif Bio plc, ...

  • PR Newswire2 months ago

    Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2018

    88 Presentations by Coalition Members During the Annual Meeting WASHINGTON , June 6, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that 13 of its member companies will present ...

  • GlobeNewswire2 months ago

    Motif Bio to present at Jefferies Global Healthcare Conference in New York

    NEW YORK, May 31, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company will give a company presentation and meet ...

  • GlobeNewswire2 months ago

    Motif Bio Appoints Stephanie Noviello, MD, MPH as Vice President, Clinical Development

    Motif Bio plc (MTFB.L) (MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that Stephanie Noviello, MD, MPH has joined the Company as Vice President, Clinical Development.  She will report to David Huang, MD, PhD, Chief Medical Officer.  Dr. Noviello will be a key contributor to the European Marketing Authorisation Application submission for iclaprim. David Huang, MD, PhD, Chief Medical Officer of Motif Bio, said: “We are delighted to have Stephanie join Motif.  Her strategic insights, experience and leadership in late-stage global clinical trials and the regulatory process, including post-marketing requirements, make her ideally suited for this position.

  • GlobeNewswire2 months ago

    Motif Bio to Present Iclaprim Data at ASM Microbe 2018

    NEW YORK, May 08, 2018-- Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that two iclaprim abstracts have been accepted for presentation ...

  • GlobeNewswire3 months ago

    Motif Bio REVIVE-2 Phase 3 Study Results with Iclaprim Published in Peer-reviewed Journal, Antimicrobial Agents and Chemotherapy

    Motif Bio plc (MTFB.L) (MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the results from REVIVE-2, a global Phase 3 clinical trial evaluating the investigational drug candidate iclaprim in patients with acute bacterial skin and skin structure infections (ABSSSI), have been published in the peer-reviewed journal, Antimicrobial Agents and Chemotherapyi. The REVIVE-2 study was a global Phase 3 trial evaluating iclaprim in patients with ABSSSI. As previously reported, the study met its primary endpoint of non-inferiority (NI) (10% margin) compared to vancomycin, the current standard of care, at the early time point (ETP), 48 to 72 hours after the start of administration of the study drug, in the intent-to-treat (ITT) patient population.

  • Zacks Small Cap Research3 months ago

    MTFB: Initiates NDA Submission for Iclaprim

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. In addition, the U.S. Food and Drug Administration (FDA) has granted iclaprim orphan drug designation (ODD) for the treatment of bacterial infections in patients with cystic fibrosis caused by Staphylococcus aureus.

  • PR Newswire3 months ago

    Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

    71 Abstracts to be Presented by Coalition Members During the Annual Meeting WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member ...

  • Is It Too Late To Buy Motif Bio plc (NASDAQ:MTFB)?
    Simply Wall St.4 months ago

    Is It Too Late To Buy Motif Bio plc (NASDAQ:MTFB)?

    Motif Bio plc (NASDAQ:MTFB), a pharmaceuticals company based in United States, saw a double-digit share price rise of over 10% in the past couple of months on the NasdaqCM. WithRead More...

  • Zacks Small Cap Research6 months ago

    MTFB: REVIVE-1 Results Published in Clinical Infectious Diseases

    Motif Bio Plc (MTFB) is a biopharmaceutical company focused on the development of antibiotic compounds for difficult to treat bacterial infections. The company’s lead asset, iclaprim, is a novel diaminopyrimidine molecule that has completed Phase 3 testing for the treatment of acute bacterial skin and skin structure infections (ABSSSI), with the company announcing positive results from the two studies earlier in 2017. The company had previously announced positive topline results from the study in April 2017.

  • PR Newswire6 months ago

    Motif Bio PLC, Spero Therapeutics, Inc. and Vical Incorporated Join Antimicrobials Working Group

    WASHINGTON, Jan. 29, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of three new members to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. Motif Bio PLC (AIM/Nasdaq: MTFB), is a clinical-stage biopharmaceutical company focused on developing novel antibiotics to treat hospitalized patients with serious and life-threatening infections caused by multi-drug resistant (MDR) bacteria. Spero Therapeutics, Inc. (SPRO), is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for MDR bacterial infections.